What You Need to Know to Help Patients Get Off to an Easy Start

BYETTA is a unique treatment option that can help patients with type 2 diabetes reach their A1C goals. Here you'll learn important points about BYETTA dosing and administration as well as the many support resources available that will help you get patients started on BYETTA therapy.

Fixed dosing, convenient storage

BYETTA comes in a prefilled pen with fixed BID dosing for all patients:

No additional glucose monitoring is required to determine the dose
No additional dose planning around meal size or amount of exercise is needed

BYETTA offers convenient storage:

Prior to first use, BYETTA must be stored refrigerated at 36°F to 46°F (2°C to 8°C)
After the BYETTA Pen is first used, it can be stored at a room temperature not to exceed 77°F (25°C)

Dosing and administration overview

BYETTA is given by subcutaneous injection in the abdomen, thigh, or upper arm
The BYETTA Pen is suitable for use with a variety of pen needles
Pen needles must be purchased separately and may require a prescription
BYETTA should be injected twice daily — anytime within 1 hour before the morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart)
BYETTA should not be administered after a meal
If a dose is missed, resume treatment with the next scheduled dose
Product information:
– 5-mcg BYETTA Pen: 5 mcg per dose, 60 doses, 1.2 mL prefilled pen NDC 66780-210-07
– 10-mcg BYETTA Pen: 10 mcg per dose, 60 doses, 2.4 mL prefilled pen NDC 66780-210-08

Patient support resources

A variety of resources are available to help get patients off to an easy start:

BYETTA By Your Side^SM Program

Free e-mail support program for patients new to BYETTA
Helpful advice from leading diabetes experts and tools to help patients manage their condition
Inspirational messages to help patients stay on course
Toll-free number that patients can call before their first injection to learn what to expect from BYETTA and how to use the BYETTA Pen: 1-800-868-1190
Have your patients visit www.BYETTAByYourSide.com to enroll in the program

BYETTA Patient Starter Kit

Patient-friendly design organized to help patients successfully start and inject BYETTA
Comprehensive training DVD featuring a certified diabetes educator
Provided to patients by their doctor — if they didn't receive one, patients should ask their doctor or visit www.BYETTA.com/starting

www.BYETTA.com
A variety of patient resources are available 24/7:

BYETTA Pen Tutorial to reinforce the training patients receive in their physician's office
Patient Education Materials, including brochures and BYETTA Pen user manuals, are available for download, some in multiple languages
Frequently Asked Questions about BYETTA basics, dosing, using the pen, and safety

Formulary access tool

This online formulary tool enables you to download PDF files listing formulary access information of insurance providers covering BYETTA in your state.

We hope these tools and resources provide you with the information you need to help get patients off to an easy start on BYETTA. Learn more about BYETTA, including efficacy and safety information.

Indication

BYETTA is indicated as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus who are taking metformin, a sulfonylurea, a thiazolidinedione, a combination of metformin and a sulfonylurea, or a combination of metformin and a thiazolidinedione, but have not achieved adequate glycemic control.

Important Safety Information

Precautions:

BYETTA is not a substitute for insulin in insulin-requiring patients. BYETTA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Patients should be observed for signs and symptoms of acute pancreatitis (persistent severe abdominal pain which may be accompanied by vomiting). If pancreatitis is suspected, BYETTA and other potentially suspect drugs should be discontinued. Resuming treatment with BYETTA is not recommended if pancreatitis is confirmed and an alternative etiology for the pancreatitis has not been identified.
Patients should be observed for signs and symptoms of hypersensitivity reactions.
BYETTA is not recommended for use in patients with end-stage renal disease, severe renal impairment, or severe gastrointestinal disease.
Patients should be observed for signs of altered renal function, including those who are taking concomitant agents known to affect renal function/hydration status, such as diuretics, ACE inhibitors and NSAIDs, or those experiencing significant vomiting and/or diarrhea, which may lead to dehydration.
Patients receiving BYETTA with a sulfonylurea have an increased risk of hypoglycemia. To reduce the risk of hypoglycemia, clinicians may consider reducing the sulfonylurea dose.

Drug Interactions:

The effect of BYETTA to slow gastric emptying may reduce the extent and rate of absorption of orally administered drugs, so it should be used with caution in patients receiving oral medications that require rapid gastrointestinal absorption.
Medications that are dependent on threshold concentrations for efficacy, such as contraceptives and antibiotics, should be taken at least 1 hour before BYETTA injection. If such drugs are to be administered with food, they should be taken with a meal or snack when BYETTA is not administered.

Adverse Reactions:

The most common adverse events associated with BYETTA were nausea, vomiting, diarrhea, feeling jittery, dizziness, headache, and dyspepsia.

For complete safety profile and other important prescribing considerations, see the Prescribing Information.